MUC16 (СА125) как иммунотерапевтическая мишень

Автор: Киселева Я.Ю., Джикия Е.Л., Кулинич Т.М., Шишкин А.М., Иванов А.В., Боженко В.К.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 4 т.16, 2016 года.

Бесплатный доступ

Резюме: MUC16 является высокомолекулярным трансмембранным гликопротеином, который экспрессируется в норме на поверхности некоторых типов эпителиальных клеток, и участвует в их защите от неблагоприятного механического воздействия и проникновения в организм различных патогенов. Антигенная детерминанта муцина 16, известная как CA125, используется в клинической диагностике для мониторинга прогрессирования заболевания и ответа на терапию пациентов с раком яичников. В статье рассмотрены структура MUC16 и его эпитопа CA125, экспрессия MUC16 и его функции в норме, значение антигена CA125 как онкомаркера и его применение в клинике, биологическая роль MUC16 в онкогенезе и метастазировании, а также его участие в механизмах ингибирования противоопухолевого иммунного ответа.

Еще

Онкомаркер, онкогенез, метастазирование

Короткий адрес: https://sciup.org/14955589

IDR: 14955589

Список литературы MUC16 (СА125) как иммунотерапевтическая мишень

Железная Л.А. Муцины -новый подкласс гликопротеинов. Успехи биол. химии. 1997. T. 37. С. 115-146.
Золотова Н.А. Структурная и функциональная характеристика муцинов. Клиническая и экспериментальная морфология. 2014. №. 1. С. 66-72.
Ando M., Tu W., Nishijima K., Lijima S. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun. 2008. V. 369. N. 3. P. 878-883.
Argueso P., Guzman-Aranguez A., Mantelli F., et al. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem. 2009. V. 284. N. 34. P. 23037-23045.
Argueso P., Spurr-Michaud S., Russo C.L., et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci. 2003. V. 44. N. 6. P. 2487-2495.
Avril T., Floyd H., Lopez F., et al. The membrane-proximal immunoreceptor tyrosinebased inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33related Siglecs expressed on human monocytes and NK cells. J Immunol. 2004. V. 173. N. 11. P. 6841-6849.
Bast R.C., Feeney M., Lazarus H., et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981. V. 68. N. 5. P. 1331-1337.
Bast R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983. V. 309. N. 15. P. 883887.
Bast R.C., Spriggs D.R. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol. 2011. V. 121. N. 3. P. 429-430.
Blalock T.D., Spurr-Michaud S.J., Tisdale A.S., et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2007. V. 48. N. 10. P. 4509-4518.
Bork P., Patthy L. The SEA module: a new extracellular domain associated with Oglycosylation. Protein Sci. 1995. V. 4. N. 7. P. 1421-1425.
Borras G., Molina R., Xercavins J., et al. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol. 1995. V. 57. N. 2. P. 205-211.
Bottoni P., Scatena R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015. V. 867. N. P. 229-244.
Bressan A., Bozzo F., Maggi C.A., et al. OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. Dis Markers. 2013. V. 34. N. 4. P. 257-267.
Caffery B., Joyce E., Heynen M.L., et al. MUC16 expression in Sjogren's syndrome, KCS, and control subjects. Mol Vis. 2008. V. 14. N. P. 2547-2555.
Chen S.H., Dallas M.R., Balzer E.M., et al. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. Faseb J. 2012. V. 26. N. 3. P. 1349-1359.
Chen S.H., Hung W.C., Wang P., et al. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013. V. 3. N. Article ID: 1870.
Comamala M., Pinard M., Theriault C., et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH: OVCAR3 ovarian carcinoma cells. Br J Cancer. 2011. V. 104. N. 6. P. 989-999.
Das S., Batra S.K. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy. Cancer Res. 2015. V. 75. N. 22. P. 4669-4674.
Das S., Majhi P.D., Al-Mugotir M.H., et al. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments. Sci Rep. 2015a. V. 5. N. Article ID: 9759.
Das S., Rachagani S., Torres-Gonzalez M.P., et al. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget. 2015b. V. 6. N. 8. P. 5772-5787.
Davies J.R., Kirkham S., Svitacheva N., et al. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int J Biochem Cell Biol. 2007. V. 39. N. 10. P. 1943-1954.
Dawson M.A., Bannister A.J., Gottgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009. V. 461. N. 7265. P. 819-822.
Devarbhavi H., Kaese D., Williams A.W., et al. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc. 2002. V. 77. N. 6. P. 538-541.
Dharma Rao T., Park K.J., Smith-Jones P., et al. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol. 2010. V. 18. N. 5. P. 462-472.
Dogru M., Matsumoto Y., Okada N., et al. Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis. Allergy. 2008. V. 63. N. 10. P. 1324-1334.
Duk J.M., Aalders J.G., Fleuren G.J., et al. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol. 1986. V. 155. N. 5. P. 1097-1102.
Duvel K., Yecies J.L., Menon S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010. V. 39. N. 2. P. 171-183.
Einama T., Kamachi H., Nishihara H., et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011. V. 40. N. 8. P. 1276-1282.
Felder M., Kapur A., Gonzalez-Bosquet J., et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014. V. 13. N. P. 129.
Giannakouros P., Comamala M., Matte I., et al. MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering beta-catenin signaling. Am J Cancer Res. 2015a. V. 5. N. 1. P. 219-230.
Giannakouros P., Matte I., Rancourt C., et al. Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail. Int J Oncol. 2015b. V. 46. N. 1. P. 91-98.
Gipson I.K. Human endocervical mucins. Ernst Schering Res Found Workshop. 2005. V. N. 52. P. 219-244.
Gipson I.K., Spurr-Michaud S., Tisdale A., et al. Comparison of the transmembrane mucins MUC1 and MUC16 in epithelial barrier function. PLoS One. 2014. V. 9. N. 6. P. e100393.
Govindarajan B., Menon B.B., Spurr-Michaud S., et al. A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrier. PLoS One. 2012. V. 7. N. 3. P. e32418.
Griffiths D.S., Li J., Dawson M.A., et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol. 2011. V. 13. N. 1. P. 13-21.
Gronowitz E., Pitkanen S., Kjellmer I., et al. Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis. Acta Paediatr. 2003. V. 92. N. 11. P. 1267-1271.
Gubbels J.A., Belisle J., Onda M., et al. Mesothelin-MUC16 binding is a high affinity, Nglycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006. V. 5. N. 1. P. 50.
Gubbels J.A., Felder M., Horibata S., et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010. V. 9. N. P. 11.
Haga Y., Sakamoto K., Egami H., et al. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci. 1986a. V. 292. N. 1. P. 25-29.
Haga Y., Sakamoto K., Egami H., et al. Clinical significance of serum CA125 values in patients with cancers of the digestive system. Am J Med Sci. 1986b. V. 292. N. 1. P. 30-34.
Halila H., Stenman U.H., Seppala M. Ovarian Cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer. 1986. V. 57. N. 7. P. 1327-1329.
Haridas D., Ponnusamy M.P., Chugh S., et al. MUC16: molecular analysis and its functional implications in benign and malignant conditions. Faseb J. 2014. V. 28. N. 10. P. 4183-4199.
Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008. V. 70. N. P. 431-457.
He C.Z., Zhang K.H., Li Q., et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013. V. 13. N. P. 87.
Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989. V. 4. N. 1. P. 1-12.
Jager K., Wu G., Sel S., et al. MUC16 in the lacrimal apparatus. Histochem Cell Biol. 2007. V. 127. N. 4. P. 433-438.
Jonckheere N., Skrypek N., Frenois F., et al. Membrane-bound mucin modular domains: from structure to function. Biochimie. 2013. V. 95. N. 6. P. 1077-1086.
Kabawat S.E., Bast R.C., Bhan A.K., et al. Tissue distribution of a coelomic-epitheliumrelated antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983. V. 2. N. 3. P. 275-285.
Kaneko O., Gong L., Zhang J., et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009. V. 284. N. 6. P. 3739-3749.
Kerschner J.E. Mucin gene expression in human middle ear epithelium. Laryngoscope. 2007. V. 117. N. 9. P. 1666-1676.
Kim N., Hong Y., Kwon D., et al. Somatic mutaome profile in human cancer tissues. Genomics Inform. 2013. V. 11. N. 4. P. 239-244.
Kramer S., Jager W., Lang N. CA 125 is an indicator for pleural metastases in breast cancer. Anticancer Res. 1997. V. 17. N. 4B. P. 2967-2970.
Lakshmanan I., Ponnusamy M.P., Das S., et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene. 2012. V. 31. N. 7. P. 805-817.
Li Y., Ren J., Yu W., et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem. 2001. V. 276. N. 38. P. 35239-35242.
Liao D.J., Thakur A., Wu J., et al. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog. 2007. V. 13. N. 2. P. 93-158.
Liu Q., Cheng Z., Luo L., et al. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with beta-catenin to promote tumorigenesis and metastasis. Oncotarget. 2016. V. N. P.
Macao B., Johansson D.G., Hansson G.C., et al. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol. 2006. V. 13. N. 1. P. 71-76.
Maeda T., Inoue M., Koshiba S., et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004. V. 279. N. 13. P. 13174-13182.
Mai P.L., Wentzensen N., Greene M.H. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila). 2011. V. 4. N. 3. P. 303306.
Mantelli F., Argueso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol. 2008. V. 8. N. 5. P. 477-483.
Marcos-Silva L., Narimatsu Y., Halim A., et al. Characterization of binding epitopes of CA125 monoclonal antibodies. J Proteome Res. 2014. V. 13. N. 7. P. 3349-3359.
Marcos-Silva L., Ricardo S., Chen K., et al. A novel monoclonal antibody to a defined peptide epitope in MUC16. Glycobiology. 2015. V. 25. N. 11. P. 1172-1182.
Masahashi T., Matsuzawa K., Ohsawa M., et al. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation. Obstet Gynecol. 1988. V. 72. N. 3 Pt 1. P. 328-331.
Matte I., Lane D., Boivin M., et al. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer. 2014. V. 14. N. P. 234.
Menon B.B., Kaiser-Marko C., Spurr-Michaud S., et al. Suppression of Toll-like receptor-mediated innate immune responses at the ocular surface by the membrane-associated mucins MUC1 and MUC16. Mucosal Immunol. 2015. V. 8. N. 5. P. 1000-1008.
Menon B.B., Zhou X., Spurr-Michaud S., et al. Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells. mSphere. 2016. V. 1. N. 1. P.
Miralles C., Orea M., Espana P., et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003. V. 10. N. 2. P. 150-154.
Molina R., Filella X., Bruix J., et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991. V. 37. N. 8. P. 1379-1383.
Niloff J.M., Klug T.L., Schaetzl E., et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984a. V. 148. N. 8. P. 1057-1058.
Niloff J.M., Knapp R.C., Schaetzl E., et al. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol. 1984b. V. 64. N. 5. P. 703-707.
O'Brien T.J., Beard J.B., Underwood L.J., et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 2001. V. 22. N. 6. P. 348-366.
O'Brien T.J., Beard J.B., Underwood L.J., et al. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol. 2002. V. 23. N. 3. P. 154-169.
O'Brien T.J., Hardin J.W., Bannon G.A., et al. CA 125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol. 1986. V. 155. N. 1. P. 50-55.
Omar Y.T., al-Naqeeb N., el Nas S.A., et al. Serum levels of CA 125 in patients with gastrointestinal cancers. Tumour Biol. 1989. V. 10. N. 6. P. 316-323.
Patankar M.S., Jing Y., Morrison J.C., et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 2005. V. 99. N. 3. P. 704-713.
Patra K.C., Wang Q., Bhaskar P.T., et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013. V. 24. N. 2. P. 213-228.
Patton P.E., Field C.S., Harms R.W., et al. CA-125 levels in endometriosis. Fertil Steril. 1986. V. 45. N. 6. P. 770-773.
Pittaway D.E., Fayez J.A. Serum CA-125 antigen levels increase during menses. Am J Obstet Gynecol. 1987. V. 156. N. 1. P. 75-76.
Rao T.D., Tian H., Ma X., et al. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One. 2015. V. 10. N. 5. P. e0126633.
Reinartz S., Failer S., Schuell T., et al. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer. 2012. V. 48. N. 10. P. 15581569.
Ricardo S., Marcos-Silva L., Pereira D., et al. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol. 2014. V. 9. N. 2. P. 503-512.
Rump A., Morikawa Y., Tanaka M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004. V. 279. N. 10. P. 9190-9198.
Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996. V. 14. N. 5. P. 1545-1551.
Shield K., Ackland M.L., Ahmed N., et al. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009. V. 113. N. 1. P. 143-148.
Shimizu A., Hirono S., Tani M., et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012. V. 103. N. 4. P. 739-746.
Shimobayashi M., Hall M.N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014. V. 15. N. 3. P. 155-162.
Shukla S.K., Gunda V., Abrego J., et al. MUC16-mediated activation of mTOR and cMyc reprograms pancreatic cancer metabolism. Oncotarget. 2015. V. 6. N. 22. P. 19118-19131.
Sikaris K.A. CA125-a test with a change of heart. Heart Lung Circ. 2011. V. 20. N. 10. P. 634-640.
Streppel M.M., Vincent A., Mukherjee R., et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012. V. 43. N. 10. P. 1755-1763.
Theriault C., Pinard M., Comamala M., et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011. V. 121. N. 3. P. 434-443.
Wen Y., Caffrey T.C., Wheelock M.J., et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem. 2003. V. 278. N. 39. P. 38029-38039.
Woo H.J., Bae C.H., Song S.Y., et al. Expression of membrane-bound mucins in human nasal mucosa: different patterns for MUC4 and MUC16. Arch Otolaryngol Head Neck Surg. 2010. V. 136. N. 6. P. 603-609.
Yamamoto M., Bharti A., Li Y., Kufe D. Interaction of the DF3/MUC1 breast carcinomaassociated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997. V. 272. N. 19. P. 12492-12494.
Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001. V. 276. N. 29. P. 27371-27375.
Zeimet A.G., Offner F.A., Muller-Holzner E., et al. Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumour Biol. 1998. V. 19. N. 4. P. 275282.

Еще

Статья обзорная